Complementinhibition mittels Eculizumab verstärkt den nephroprotektiven Effekt von ACE-Inhibitoren in einem COL4A3-Knockout-Mausmodell für das Alport-Syndrom
Details
The content you want is available to Zendy users.Already have an account? Click here. to sign in.